Seeking Alpha

Repros Therapeutics (RPRX -1%) says the FDA has scheduled a meeting to discuss the Phase 2 tests...

Repros Therapeutics (RPRX -1%) says the FDA has scheduled a meeting to discuss the Phase 2 tests for its low dose oral Proellex treatment for endometriosis. The teleconference will be held during the last week of August.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector